- Genocea Biosciences (GNCA) has filed to to raise $75M in an IPO in order to help finance the development of two early stage T-cell vaccines against herpes and all strains of the pneumococcus bacteria, a major cause of pneumonia. The company's technology could also have applications for cancer immunotherapy.
- The filing comes just days after Genocea started the Phase I study of its pneumococcus vaccine, which the company believes has the potential to be more effective than Pfizer's blockbuster Prevnar 13 treatment.
- Genocea's existing investors include the Bill & Melinda Gates Foundation and Johnson & Johnson.
- The company's submission comes towards the end of one of the best years for biotech IPOs in a decade following a long period of drought.
- ETF: IPO
Biotech startup Genocea seeks $75M in IPO
Dec 24 2013, 07:37 ET